Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease 3. Rapid correction of low vitamin D status in nursing home residents 4. 2008 Exclusive Survey—Earnings: Good news for primary care income 5. Medicare pay-for-reporting effort draws fire from frustrated doctors
Your Article Summary
Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): A phase II, randomised, dose-ranging study
The Lancet - Early Online Publication, 06/15/09
Henry RR et al. – Short-term clinical data show a favorable safety and efficacy profile for the dual peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonist aleglitazar.
Methods- SYNCHRONY study: double-blind study to establish glucose-lowering and lipid-modifying effects and safety profile of aleglitazar
- Enrollment of type 2 diabetes pts (either drug-naive or pre-treated with ≤2 oral agents) from 47 sites in 7 countries
- Single-blind, placebo run-in period of 4-5 wks
- Randomization of 332 pts double-blind to 16 wk-treatment with aleglitazar at once-daily doses of 50, 150, 300, or 600, or matching placebo (55 pts in each group), or to open-label pioglitazone 45 mg once daily (57 pts) as a reference
- Primary efficacy endpoint: change in glycosylated hemoglobin (HbA1c) concentration from baseline to treatment end
- Efficacy analysis of pts who received ≥1 dose of study drug and had ≥1 evaluable post-baseline HbA1c measurement
- Aleglitazar significantly reduced baseline HbA1c vs placebo in a dose-dependent manner
- Trend of changes over time suggests that maximum effect of aleglitazar on HbA1c concentration not yet reached after 16 wks of treatment
- Edema, hemodilution, and weight gain occurred in a dose-dependent manner
- At aleglitazar doses <300 microg, no pts had congestive heart failure, similar frequency to placebo for edema and less than with pioglitazone, and bodyweight gain was less than with pioglitazone
Today in Basic Science/Genetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Cytotoxic T lymphocyte antigen-4 Ala17 polymorphism is a genetic marker of autoimmune adrenal insufficiency: Italian association study and meta-analysis of European studies
European Journal of Endocrinology, 11/05/09
PTH and IL21R May Underlie Variation of Femoral Neck Bone Mineral Density as Revealed by a Genome-Wide Association Study
Journal of Bone and Mineral Research, 11/03/09
Bone signaling pathways and treatment of osteoporosis
Expert Review of Endocrinology & Metabolism, 11/10/09
Today in Diabetes...keeping you current
Receive free subspecialty "5-minute updates" via email
Carbohydrate-restricted diets for obesity and related diseases: An update
Current Atherosclerosis Reports, 11/17/09
Effects of Walnut Consumption on Endothelial Function in Type 2 Diabetics: A Randomized, Controlled, Cross-Over Trial
Diabetes Care, 11/04/09
Effect of Rosiglitazone, Metformin, and Glyburide on Bone Biomarkers in Patients with Type 2 Diabetes
Journal of Clinical Endocrinology and Metabolism, 11/10/09
Sponsor
Article Search
Sponsor


See Latest Articles


